AR084163A1 - Metodo para el diagnostico de un carcinoma y usos del mismo - Google Patents

Metodo para el diagnostico de un carcinoma y usos del mismo

Info

Publication number
AR084163A1
AR084163A1 ARP110104547A ARP110104547A AR084163A1 AR 084163 A1 AR084163 A1 AR 084163A1 AR P110104547 A ARP110104547 A AR P110104547A AR P110104547 A ARP110104547 A AR P110104547A AR 084163 A1 AR084163 A1 AR 084163A1
Authority
AR
Argentina
Prior art keywords
carcinoma
stem cells
epithelial
marker
sample
Prior art date
Application number
ARP110104547A
Other languages
English (en)
Inventor
Michele Barone
Leo Alfredo Di
Maria Teresa Rotelli
Filippo Batista
Donato Altomare
Original Assignee
Thd Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thd Spa filed Critical Thd Spa
Publication of AR084163A1 publication Critical patent/AR084163A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

Método para diagnosticar un carcinoma o una enfermedad residual asociada a este, o para el pronóstico de un carcinoma, o para controlar la efectividad de una terapia antitumoral dirigida contra un carcinoma, o para controlar el seguimiento de un individuo afectado por un carcinoma, en particular carcinoma colorrectal, carcinoma del estómago, carcinoma mamario, carcinoma pulmonar o carcinoma de próstata, carcinoma de hígado, carcinoma de ovarios, carcinoma de rincón, carcinoma de tiroides, carcinoma de vejiga o carcinoma de páncreas. El método consiste en colocar células madre adultas en contacto con una muestra de un hemoderivado del individuo por analizar y en verificar la expresión de al menos un marcador epitelial en las células madre por medio de inmunofluorescencia, inmunohistoquímica, ELISA o RT-PCR.Reivindicación 17: Un kit para realizar el método de acuerdo con cualquiera de las reivindicaciones de 1 a 16, que comprende: al menos un anticuerpo dirigido contra un marcador epitelial, donde dicho anticuerpo con preferencia se conjuga con un fluorocromo o con una enzima, o al menos un par de oligonucleótidos para la amplificación de al menos un marcador de tipo epitelial; y/o, una muestra de células madre; y/o, un medio para cultivar dichas células madre.
ARP110104547A 2010-12-06 2011-12-05 Metodo para el diagnostico de un carcinoma y usos del mismo AR084163A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2010/000484 WO2012077139A1 (en) 2010-12-06 2010-12-06 Method for the diagnosis of a carcinoma and uses thereof

Publications (1)

Publication Number Publication Date
AR084163A1 true AR084163A1 (es) 2013-04-24

Family

ID=44146327

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104547A AR084163A1 (es) 2010-12-06 2011-12-05 Metodo para el diagnostico de un carcinoma y usos del mismo

Country Status (15)

Country Link
US (1) US9347953B2 (es)
EP (1) EP2649445B1 (es)
JP (1) JP6018074B2 (es)
KR (1) KR20140034124A (es)
CN (1) CN103384824B (es)
AR (1) AR084163A1 (es)
AU (1) AU2010365277B2 (es)
BR (1) BR112013013869A2 (es)
CA (1) CA2819390A1 (es)
HK (1) HK1186247A1 (es)
IL (1) IL226570A (es)
RU (1) RU2013126024A (es)
SA (1) SA111330026B1 (es)
SG (1) SG191028A1 (es)
WO (1) WO2012077139A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX360236B (es) 2012-06-27 2018-10-26 Berg Llc Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
WO2016094425A1 (en) 2014-12-08 2016-06-16 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
CN106093432A (zh) * 2016-06-13 2016-11-09 厦门大学 基于联合检测fgf1、fgf10和il6的乳腺癌诊断试剂盒
KR101847435B1 (ko) 2016-09-30 2018-04-10 부경대학교 산학협력단 부갑상선 실시간 이미징 장치
CN106478820A (zh) * 2016-10-10 2017-03-08 米度（南京）生物技术有限公司 一种肝癌pet诊断示踪剂及其制备方法与用途
EP3534713A4 (en) * 2016-11-02 2020-05-27 AAL Scientifics, Inc. NON-MESENCHYMATORY HUMAN PULMONARY STEM CELLS AND METHODS OF USE THEREOF FOR TREATING RESPIRATORY DISEASES
CN106944163A (zh) * 2017-01-24 2017-07-14 瑞汉智芯医疗科技(嘉善)有限公司 一种针对尿路上皮癌的尿脱落肿瘤细胞的免疫荧光染色技术

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE259419T1 (de) 1996-03-15 2004-02-15 Munin Corp Humanes cyr61, ein signalmolekül der extrazellulaeren matrix
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
CN100536919C (zh) * 2001-01-09 2009-09-09 贝勒研究院 干扰素拮抗剂和Flt3L拮抗剂的用途
US7150990B2 (en) * 2002-03-06 2006-12-19 Reprocell, Inc. Self-renewing pluripotent hepatic stem cells
EP1540002A2 (en) * 2002-09-12 2005-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for detection of micro-metastasis
GB0320877D0 (en) 2003-09-05 2003-10-08 Celltech R&D Ltd A protein involved in carcinoma
ITPD20030264A1 (it) 2003-10-30 2005-04-30 Xeptagen Spa Metodo di diagnosi altamente specifico per neoplasie
US20050233449A1 (en) * 2004-04-16 2005-10-20 Kuan-Der Lee Simple and rapid derivation of functional hepatocytes from human bone marrow-derived mesenchymal stem cells
CA2579764A1 (en) * 2004-08-10 2006-02-23 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
WO2007089945A2 (en) 2006-02-02 2007-08-09 The Trustees Of Columbia University In The City Of New York Treating diseases by targeting silt3
CN101669031A (zh) * 2007-02-27 2010-03-10 森托科隆股份公司 使用与细胞外标记物结合的试剂组多重检测肿瘤细胞
EP2333047A1 (en) * 2009-12-09 2011-06-15 Fresenius Medical Care Deutschland GmbH Adult stem cell derived conditioned medium and/or adult stem cells for use in the therapeutic treatment of a tumor disease

Also Published As

Publication number Publication date
CN103384824B (zh) 2016-02-03
SA111330026B1 (ar) 2015-04-06
US9347953B2 (en) 2016-05-24
IL226570A (en) 2016-05-31
AU2010365277A1 (en) 2013-06-13
JP2014500026A (ja) 2014-01-09
US20130316361A1 (en) 2013-11-28
JP6018074B2 (ja) 2016-11-02
WO2012077139A1 (en) 2012-06-14
EP2649445A1 (en) 2013-10-16
SG191028A1 (en) 2013-07-31
HK1186247A1 (en) 2014-03-07
KR20140034124A (ko) 2014-03-19
BR112013013869A2 (pt) 2016-12-06
AU2010365277B2 (en) 2017-01-05
RU2013126024A (ru) 2015-01-20
CA2819390A1 (en) 2012-06-14
CN103384824A (zh) 2013-11-06
WO2012077139A8 (en) 2012-08-16
EP2649445B1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
AR084163A1 (es) Metodo para el diagnostico de un carcinoma y usos del mismo
MX2021006510A (es) Nanomotores impulsados por enzimas funcionalizados.
PA8854201A1 (es) Anticuerpos humanos de alta afinidad contra pcsk9
MX367042B (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-dp-1 para tratar cancer.
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
CL2007003622A1 (es) Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
EA201500219A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
WO2011133668A3 (en) Methods and compositions for the treatment of cancer
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
WO2012154567A3 (en) Human invasion signature for prognosis of metastatic risk
WO2008115750A3 (en) Compositions and methods for the treatment of cancer
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
Kaji et al. Properties of L-type amino acid transporter 1 in epidermal ovarian cancer
WO2009055823A3 (en) Method to predict responsiveness of breast cancer to polyaminetype chemotherapy
WO2011112903A3 (en) Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
WO2009004484A3 (en) Trim24 (tifla) as p53 modulator and cancer target
AU2018275891A1 (en) Articles of manufacture and methods related to toxicity associated with cell therapy
PH12015500388A1 (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
CY1117701T1 (el) Δραστηριοτητα του τέμσιρολιμου κατα των ογκων στον καρκινο θηλοειδων νεφρικων κυτταρων
WO2014169011A3 (en) Methods for treating immune diseases
BR112013001879A2 (pt) "método para aprefeiçoar o efeito de tratamento em um paciente que sofre de câncer gástrico, método in vitro, kit, uso de um olignucleotídeo ou polipetídio e uso de bevacizumabe"
WO2012019125A3 (en) Biomarkers for prostate cancer and methods for their detection
WO2010093907A3 (en) An assay for the detection of recurrence in breast cancer using the novel tumor suppressor dear1

Legal Events

Date Code Title Description
FB Suspension of granting procedure